Valuation check: 6929.TWO's profit margin is -2.43%, below the sector sector average of 13.2%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
We Can Medicines , Ltd. posts a profit margin of -2.43% as of June 2026. That compares with -2.28% in the prior-year period — down 6.9% year over year. That is below the sector sector average of 13.2%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, We Can Medicines , Ltd.'s profit margin was -2.28%. The latest reading is -2.43% — a 6.9% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.
For its sector stocks, a profit margin near 13.2% is typical. We Can Medicines , Ltd.'s -2.43% is lower that level. That is roughly 118.4% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
We Can Medicines , Ltd.'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -2.43% as of June 2026; use YoY and peer views to separate noise from signal.
Context for 6929.TWO's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.2%), and (3) consistency with growth and profitability. This page covers the first two; We Can Medicines , Ltd.'s other metric pages and overview cover the third.